Tadanord (Tablets) Instructions for Use

Marketing Authorization Holder

Zvezda Media, LLC (Russia)

Manufactured By

Severnaya Zvezda NAO (Russia)

ATC Code

G04BE08 (Tadalafil)

Active Substance

Tadalafil (Rec.INN registered by WHO)

Dosage Forms

	Tadanord	Film-coated tablets, 5 mg: 20 or 30 pcs.
		Film-coated tablets, 20 mg: 4, 7, 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Film-coated tablets yellow in color, round, biconvex, with a score on one side; the core of the tablet on the cross-section is white or almost white.

Excipients: lactose monohydrate (milk sugar) – 53.8 mg, lactose monohydrate (lactopress) (milk sugar) – 64 mg, microcrystalline cellulose 102 – 26 mg, croscarmellose sodium (primellose) – 12.5 mg, crospovidone (Kollidon CL-M) – 4 mg, crospovidone (Kollidon CL) – 3 mg, hyprolose extra fine (hydroxypropylcellulose) – 3 mg, hyprolose (hydroxypropylcellulose) – 2 mg, sodium stearyl fumarate – 1.5 mg, sodium lauryl sulfate – 0.2 mg.

Shell composition hypromellose – 2.5 mg, polysorbate-80 (tween-80) – 1 mg, talc – 1 mg, titanium dioxide (E171) – 0.49 mg, quinoline yellow dye (E104) – 0.01 mg.

10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer bottles (1) – cardboard packs.

Film-coated tablets pinkish-orange in color, round, biconvex; the core of the tablet on the cross-section is white or almost white.

Excipients: lactose monohydrate (milk sugar) – 100.2 mg, lactose monohydrate (lactopress) (milk sugar) – 123 mg, microcrystalline cellulose 102 – 53 mg, croscarmellose sodium (primellose) – 17 mg, crospovidone (Kollidon CL-M) – 5 mg, crospovidone (Kollidon CL) – 2 mg, hyprolose extra fine (hydroxypropylcellulose) – 5 mg, hyprolose (hydroxypropylcellulose) – 2 mg, sodium stearyl fumarate – 2 mg, sodium lauryl sulfate – 0.8 mg.

Shell composition hypromellose – 5 mg, polysorbate-80 (tween-80) – 2 mg, talc – 2 mg, titanium dioxide (E171) – 0.8 mg, aluminum lake based on sunset yellow FCF dye (E110) – 0.2 mg.

10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Erectile dysfunction treatment drug. PDE5 inhibitor

Pharmacotherapeutic Group

Drugs used in urology; drugs for the treatment of erectile dysfunction

Pharmacological Action

Tadalafil is a drug for the treatment of erectile dysfunction and is a reversible selective inhibitor of specific cGMP PDE5. When sexual stimulation causes local release of nitric oxide, inhibition of PDE5 by tadalafil leads to increased levels of cGMP in the corpus cavernosum of the penis. The consequence of this is relaxation of the smooth muscles of the arteries and increased blood flow to the penile tissues, which causes an erection. Tadalafil is ineffective in the absence of sexual stimulation.

In vitro studies have shown that Tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme found in the smooth muscles of the corpus cavernosum, in the smooth muscles of visceral vessels, in skeletal muscles, platelets, kidneys, lungs, and cerebellum.

The effect of tadalafil on PDE5 is more potent than on other phosphodiesterases. Tadalafil is 10,000 times more potent against PDE5 than against PDE1, PDE2, PDE4, which are localized in the heart, brain, blood vessels, liver and other organs. Tadalafil blocks PDE5 10,000 times more potently than PDE3, an enzyme found in the heart and blood vessels. This selectivity for PDE5, compared to PDE3, is important because PDE3 is an enzyme involved in myocardial contraction. Furthermore, Tadalafil is approximately 700 times more potent against PDE5 than against PDE6, found in the retina and responsible for phototransduction. Tadalafil is also 10,000 times more potent against PDE5 compared to its effect on PDE7-PDE10.

It acts for 36 hours. The effect appears as early as 16 minutes after oral administration in the presence of sexual stimulation.

In healthy individuals, Tadalafil does not cause a significant change in systolic and diastolic blood pressure compared to placebo in the supine position (mean maximum decrease is 1.6/0.8 mmHg, respectively) and standing (mean maximum decrease is 0.2/4.6 mmHg, respectively). Tadalafil does not cause a significant change in heart rate.

Tadalafil does not cause changes in color discrimination (blue/green), which is explained by its low affinity for PDE6. Furthermore, no effect of tadalafil on visual acuity, electroretinogram, intraocular pressure, or pupil size was noted.

No clinically significant effect on sperm characteristics was found in men taking Tadalafil in daily doses for 6 months.

Pharmacokinetics

After oral administration, Tadalafil is rapidly absorbed. C_max is reached on average after 2 hours. The rate and extent of absorption do not depend on food intake. The pharmacokinetics of tadalafil in healthy individuals are linear with respect to time and dose. In the dose range from 2.5 to 20 mg, AUC increases proportionally to the dose. C_ss in plasma is reached within 5 days when taking the drug once a day.

The pharmacokinetics of tadalafil in patients with erectile dysfunction are similar to the pharmacokinetics of the drug in individuals without erectile dysfunction.

V_d is about 63 L, indicating that Tadalafil is distributed in body tissues. At therapeutic concentrations, 94% of tadalafil is bound to plasma proteins. In healthy individuals, less than 0.0005% of the administered dose was found in semen.

It is metabolized with the participation of the isoenzyme CYP3A4. The main circulating metabolite is methylcatechol glucuronide, which is 13,000 times less active against PDE5 than Tadalafil, so it is unlikely that this metabolite is clinically significant.

In healthy individuals, the average clearance of tadalafil after oral administration is 2.5 L/h, and the average T_1/2 is 17.5 hours. Tadalafil is excreted mainly as inactive metabolites, mostly in feces (about 61%) and to a lesser extent in urine (about 36%).

In patients with mild (creatinine clearance from 51 to 80 ml/min) or moderate (creatinine clearance from 31 to 50 ml/min) renal impairment, AUC is higher than in healthy individuals.

Indications

Erectile dysfunction.

ICD codes

Dosage Regimen

For on-demand treatment of erectile dysfunction, take one 20 mg tablet at least 16 minutes before anticipated sexual activity.

The drug can be taken with or without food. The therapeutic effect can occur at any time within a 36-hour window after administration.

Do not exceed a maximum frequency of one dose per 24-hour period.

For once-daily use, the recommended dose is 5 mg taken at approximately the same time each day, irrespective of sexual activity.

This regimen is suitable for patients anticipating frequent sexual activity (e.g., twice weekly).

In patients with mild or moderate renal impairment (creatinine clearance 30-80 mL/min), a maximum single dose of 10 mg is recommended for on-demand use.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the maximum recommended dose is 5 mg for on-demand use. The once-daily 5 mg regimen is not recommended for this patient group.

In patients with mild or moderate hepatic impairment (Child-Pugh class A or B), the maximum recommended dose is 10 mg for on-demand use.

The once-daily 5 mg regimen is not recommended for patients with hepatic impairment. Use in severe hepatic impairment is not studied and therefore not recommended.

For elderly patients, no initial dose adjustment is required. Consider a lower starting dose based on individual tolerance and underlying health status.

Adverse Reactions

Most frequently headache, dyspepsia.

Possible back pain, myalgia, nasal congestion, flushing.

Rarely eyelid edema, eye pain, conjunctival hyperemia, dizziness.

Contraindications

Concomitant use of drugs containing any organic nitrates; childhood and adolescence under 18 years of age; hypersensitivity to tadalafil.

Use in Pregnancy and Lactation

The drug is not used in women.

Use in Hepatic Impairment

With particular caution and only in case of extreme necessity, the use of tadalafil in patients with severe hepatic impairment is possible.

Use in Renal Impairment

With particular caution and only in case of extreme necessity, the use of tadalafil in patients with severe renal impairment (creatinine clearance ≤30 ml/min) is possible.

During treatment with tadalafil, back pain was more frequently noted in patients with moderate renal impairment (creatinine clearance from 31 to 50 ml/min) compared to patients with mild renal impairment (creatinine clearance from 51 to 80 ml/min) or healthy volunteers. In patients with creatinine clearance ≤50 ml/min, tadalafil should be used with caution.

Pediatric Use

Contraindicated in children and adolescents under 18 years of age.

Special Precautions

With particular caution and only in case of extreme necessity, the use of tadalafil in patients with severe renal impairment (creatinine clearance ≤30 ml/min) and severe hepatic impairment is possible.

During treatment with tadalafil, back pain was more frequently noted in patients with moderate renal impairment (creatinine clearance from 31 to 50 ml/min) compared to patients with mild renal impairment (creatinine clearance from 51 to 80 ml/min) or healthy volunteers. In patients with creatinine clearance ≤50 ml/min, Tadalafil should be used with caution.

Therefore, treatment of erectile dysfunction, including with the use of tadalafil, should not be carried out in men with such heart diseases where sexual activity is not recommended.

The potential risk of complications during sexual activity in patients with cardiovascular diseases should be taken into account: myocardial infarction within the last 90 days; unstable angina or angina occurring during sexual intercourse; chronic heart failure (functional class II and higher according to the NYHA classification) that developed within the last 6 months; uncontrolled cardiac arrhythmias; arterial hypotension (BP less than 90/50 mmHg) or uncontrolled arterial hypertension; stroke within the last 6 months.

Tadalafil should be used with caution in patients predisposed to priapism (for example, with sickle cell anemia, multiple myeloma, or leukemia) or in patients with anatomical deformation of the penis (for example, angulation, cavernous fibrosis, or Peyronie’s disease).

The patient should be informed of the need to immediately consult a doctor in case of an erection lasting 4 hours or more. Untimely treatment of priapism leads to damage to penile tissues, as a result of which long-term loss of potency may occur.

No cases of priapism have been reported during the use of tadalafil.

It is not recommended to use Tadalafil in combination with other types of treatment for erectile dysfunction.

Drug Interactions

Tadalafil is mainly metabolized with the participation of the enzyme CYP3A4. The selective CYP3A4 inhibitor ketoconazole increases AUC by 107%, and rifampicin reduces it by 88%.

Although specific interactions have not been studied, it can be assumed that such protease inhibitors as ritonavir and saquinavir, as well as CYP3A4 inhibitors such as erythromycin and itraconazole, increase the activity of tadalafil.

When taking an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil simultaneously, the absorption rate of the latter decreases without changing its AUC.

Tadalafil enhances the hypotensive effect of nitrates. This occurs as a result of the additive action of nitrates and tadalafil on the metabolism of nitric oxide and cGMP. Therefore, the use of tadalafil in patients receiving nitrates is contraindicated.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.